newsfilter
← Earnings
Earnings Releases·

Cue Biopharma — Third Quarter 2026 Earnings Summary

Cue Biopharma reported third-quarter 2026 financial results showing a net loss of $50.0 million and revenue of $0.1 million, driven by increased clinical trial costs and non-cash stock-based compensation. The company announced positive Phase 2 results for its lead candidate CUE-221 in chronic spontaneous urticaria, demonstrating superior complete hive resolution compared to placebo and XOLAIR, particularly in patients with high baseline IgE. Additionally, Cue Biopharma initiated first-in-human dosing for CUE-401, a dual-agonist therapeutic candidate designed to treat autoimmune diseases, while its Investigational New Drug application for CUE-221 in food allergy received FDA clearance.

Company
CUE BIOPHARMA INC
Sector
Healthcare
Industry
Biotechnology